Immunogenicity and Safety of a 9-valent Human Papillomavirus Vaccine in HIV-positive Women

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

158

Participants

Timeline

Start Date

February 12, 2020

Primary Completion Date

September 30, 2024

Study Completion Date

December 30, 2024

Conditions

HIV InfectionsHPV Infection

Interventions

BIOLOGICAL

Human Papillomavirus 9-valent Vaccine, Recombinant

Vaccine administrated

Trial Locations (1)

Hospital Universitario Virgen de Las Nieves, Granada

All Listed Sponsors

collaborator

Instituto de Salud Carlos III

OTHER_GOV

lead

University Hospital Virgen de las Nieves

OTHER